ATE446768T1 - Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden - Google Patents

Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden

Info

Publication number: ATE446768T1
Authority: AT; Austria
Prior art keywords: factor vii; compositions; aqueous pharmaceutical; liquid; pharmaceutical composition
Prior art date: 2003-07-01

Application number

AT04738962T

Other languages

English (en)

Inventor

Michael Jensen

Birthe Hansen

Troels Kornfelt

Kirsten Jakobsen

Original Assignee

Novo Nordisk Healthcare Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-01

Filing date

2004-06-30

Publication date

2009-11-15

2004-03-18 Priority claimed from PCT/DK2004/000181 external-priority patent/WO2004082708A2/en

2004-06-30 Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE446768T1 publication Critical patent/ATE446768T1/de

Links

229940012413 factor vii Drugs 0.000 title abstract 4
239000007788 liquid Substances 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
229920001184 polypeptide Polymers 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
108010023321 Factor VII Proteins 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 4
102100023804 Coagulation factor VII Human genes 0.000 abstract 3
229910052751 metal Inorganic materials 0.000 abstract 3
239000002184 metal Substances 0.000 abstract 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract 2
108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract 1
229940122295 Clotting factor inhibitor Drugs 0.000 abstract 1
102000016519 Coagulation factor VII Human genes 0.000 abstract 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
201000003542 Factor VIII deficiency Diseases 0.000 abstract 1
208000032843 Hemorrhage Diseases 0.000 abstract 1
208000027276 Von Willebrand disease Diseases 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
239000003146 anticoagulant agent Substances 0.000 abstract 1
229940127219 anticoagulant drug Drugs 0.000 abstract 1
230000000740 bleeding effect Effects 0.000 abstract 1
239000003114 blood coagulation factor Substances 0.000 abstract 1
239000006172 buffering agent Substances 0.000 abstract 1
230000015556 catabolic process Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
229910052804 chromium Inorganic materials 0.000 abstract 1
239000011651 chromium Substances 0.000 abstract 1
229940105772 coagulation factor vii Drugs 0.000 abstract 1
229910017052 cobalt Inorganic materials 0.000 abstract 1
239000010941 cobalt Substances 0.000 abstract 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
229910052802 copper Inorganic materials 0.000 abstract 1
239000010949 copper Substances 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
238000006731 degradation reaction Methods 0.000 abstract 1
201000007386 factor VII deficiency Diseases 0.000 abstract 1
208000009429 hemophilia B Diseases 0.000 abstract 1
208000031169 hemorrhagic disease Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
229910052742 iron Inorganic materials 0.000 abstract 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
150000002739 metals Chemical class 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229910052759 nickel Inorganic materials 0.000 abstract 1
239000002736 nonionic surfactant Substances 0.000 abstract 1
230000003647 oxidation Effects 0.000 abstract 1
238000007254 oxidation reaction Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
206010043554 thrombocytopenia Diseases 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04738962T 2003-07-01 2004-06-30 Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden ATE446768T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DKPA200300995		2003-07-01
US48533403P	2003-07-07	2003-07-07
PCT/DK2004/000181 WO2004082708A2 (en)	2003-03-18	2004-03-18	Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
PCT/DK2004/000465 WO2005002615A1 (en)	2003-07-01	2004-06-30	Liquid, aqueous pharmaceutical composition of factor vii polypeptides

Publications (1)

Publication Number	Publication Date
ATE446768T1 true ATE446768T1 (de)	2009-11-15

Family

ID=36697628

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04738962T ATE446768T1 (de)	2003-07-01	2004-06-30	Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden

Country Status (7)

Country	Link
US (2)	US20060166882A1 (de)
EP (1)	EP1644030B1 (de)
JP (2)	JP5306597B2 (de)
AT (1)	ATE446768T1 (de)
DE (1)	DE602004023848D1 (de)
ES (1)	ES2335994T3 (de)
WO (1)	WO2005002615A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1671410B (zh)	2002-06-21	2010-05-12	诺和诺德医疗保健公司	因子ⅶ多肽的稳定化固体组合物
WO2005002615A1 (en) *	2003-07-01	2005-01-13	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP4874806B2 (ja)	2003-12-01	2012-02-15	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	液体因子ｖｉｉ組成物のウイルス濾過
CN1917861B (zh) *	2003-12-19	2012-03-21	诺和诺德医疗保健公司	因子vii多肽的稳定化固体组合物
CN101184474B (zh) *	2005-04-28	2013-05-29	诺和诺德医疗保健公司	含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法
CN104887620A (zh)	2007-05-02	2015-09-09	诺沃—诺迪斯克保健股份有限公司	包括芳香族防腐剂和抗氧化剂的高浓度因子vii多肽制剂
WO2009141418A1 (en) *	2008-05-23	2009-11-26	Novo Nordisk A/S	Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
AR102331A1 (es) *	2014-08-12	2017-02-22	Baxalta Inc	Activación del factor x

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2916711A1 (de) *	1979-04-25	1980-11-06	Behringwerke Ag	Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4956386A (en) *	1980-04-25	1990-09-11	Gist-Brocades N.V.	Pharmaceutical compositions and process for their preparation
US4404132A (en) *	1980-05-27	1983-09-13	Cutter Laboratories, Inc.	Blood coagulation promoting product
CA1182748A (en) *	1980-11-21	1985-02-19	Gerard Marx	Method for synthesizing procoagulant factor viii activity
US4495278A (en) *	1981-04-27	1985-01-22	Baxter Travenol Laboratories, Inc.	Process for making novel blood clotting enzyme compositions
US4382083A (en) *	1981-06-25	1983-05-03	Baxter Travenol Laboratories, Inc.	Therapeutic method for treating blood-clotting defects with factor VIIa
GR860984B (en) *	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
US5180583A (en) *	1985-11-26	1993-01-19	Hedner Ulla K E	Method for the treatment of bleeding disorders
US5595886A (en) *	1986-01-27	1997-01-21	Chiron Corporation	Protein complexes having Factor VIII:C activity and production thereof
EP0317376B2 (de) *	1987-10-23	1996-04-03	Centre Regional De Transfusion Sanguine De Lille	Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat
US5472850A (en) *	1991-04-10	1995-12-05	Oklahoma Medical Research Foundation	Quantitative clotting assay for activated factor VII
ATE180834T1 (de) *	1990-01-29	1999-06-15	Zymogenetics Inc	Antikoagulierende proteine
US5997864A (en) *	1995-06-07	1999-12-07	Novo Nordisk A/S	Modified factor VII
US5817788A (en) *	1991-02-28	1998-10-06	Zymogenetics, Inc.	Modified factor VII
US5833982A (en) *	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
WO1993022336A1 (en) *	1992-04-30	1993-11-11	Alpha Therapeutic Corporation	Improved solubilization and stabilization of factor viii complex
DK38293D0 (da)	1993-03-31	1993-03-31	Novo Nordisk As	Fremstilling af proteiner
SE9301581D0 (sv) *	1993-05-07	1993-05-07	Kabi Pharmacia Ab	Protein formulation
WO1995003332A1 (en) *	1993-07-23	1995-02-02	Baxter International Inc.	Activated human factor viii and method of preparation
US6277828B1 (en) *	1993-08-20	2001-08-21	Syntex (U.S.A.) Inc.	Pharmaceutical formulations of nerve growth factor
US5576291A (en) *	1993-09-13	1996-11-19	Baxter International Inc.	Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
US5396670A (en) *	1993-10-08	1995-03-14	Guardian Products, Inc.	Sling for a patient lifter
IL113010A (en) *	1994-03-31	1999-10-28	Pharmacia & Upjohn Ab	Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
DE4435520A1 (de) *	1994-10-04	1996-04-11	Immuno Ag	Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
SE9403915D0 (sv) *	1994-11-14	1994-11-14	Annelie Almstedt	Process A
US5649959A (en) *	1995-02-10	1997-07-22	Sherwood Medical Company	Assembly for sealing a puncture in a vessel
US5993795A (en) *	1995-11-09	1999-11-30	Takemoto Yushi Kabushiki Kaisha	Protein composition derived from sesame seed and use thereof
US5925738A (en) *	1995-12-01	1999-07-20	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
US6320029B1 (en) *	1996-11-29	2001-11-20	The American National Red Cross	Methods of production and use of liquid formulations of plasma proteins
US5830852A (en) *	1995-12-19	1998-11-03	Cobra Therapeutics, Ltd.	Compositions for insulin-receptor mediated nucleic acid delivery
US5770700A (en) *	1996-01-25	1998-06-23	Genetics Institute, Inc.	Liquid factor IX formulations
US5763401A (en) *	1996-07-12	1998-06-09	Bayer Corporation	Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US5927739A (en) *	1996-10-07	1999-07-27	Evling; Jens	Dual friction wheelchair hand rim
US5804420A (en) *	1997-04-18	1998-09-08	Bayer Corporation	Preparation of recombinant Factor VIII in a protein free medium
US6461610B1 (en) *	1997-07-18	2002-10-08	Novo Nordisk A/S	Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
US6310183B1 (en) *	1997-09-10	2001-10-30	Novo Nordisk A/S	Coagulation factor VIIa composition
DK1820516T3 (da) *	1999-02-22	2013-10-28	Univ Connecticut	Nye albuminfrie faktor VIII-præparater
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
US20010031721A1 (en) *	1999-05-05	2001-10-18	Chandra Webb	Highly concentrated, lyophilized, and liquid factor IX formulations
DE60024268T2 (de) *	1999-07-13	2006-08-03	Biovitrum Ab	Zusammensetzungen mit stabilem faktor viii
US6586574B1 (en) *	1999-08-17	2003-07-01	Nn A/S	Stabilization of freeze-dried cake
US6750053B1 (en) *	1999-11-15	2004-06-15	I-Stat Corporation	Apparatus and method for assaying coagulation in fluid samples
CA2739933A1 (en) *	2000-02-11	2001-08-16	Bayer Healthcare Llc	Factor vii or viia-like molecules
EP1280548B1 (de) *	2000-05-03	2013-12-11	Novo Nordisk Health Care AG	Subkutane Verabreichung des Koagulationsfaktor VII
US7015194B2 (en) *	2000-05-10	2006-03-21	Novo Nordisk A/S	Pharmaceutical composition comprising factor VIIa and anti-TFPI
BR0114373A (pt) *	2000-10-02	2004-02-17	Novo Nordisk As	Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
WO2002038162A1 (en) *	2000-11-09	2002-05-16	The Scripps Research Institute	MODIFIED FACTOR VIIa
DE50114021D1 (de) *	2001-01-08	2008-07-24	Csl Behring Gmbh	Stabilisierte Flüssigzubereitung der den Blutgerinnungsfaktor VII aktivierenden Protease oder ihres Proenzyms
US6825323B2 (en) *	2001-01-10	2004-11-30	The United States Of America As Represented By The Secretary Of The Army	Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
EP1378209B1 (de)	2001-03-06	2010-05-19	Atsushi Takahashi	Gerät zum sammeln von autogenem knochenmaterial
JP4813017B2 (ja) *	2001-07-10	2011-11-09	一般財団法人化学及血清療法研究所	薬剤学的に安定な止血用組成物
US6858587B2 (en) *	2001-11-02	2005-02-22	Novo Nordisk Pharmaceuticals, Inc.	Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US7125846B2 (en) *	2001-11-09	2006-10-24	Novo Nordisk Healthcare A/G	Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
WO2003039585A1 (en) *	2001-11-09	2003-05-15	Novo Nordisk Health Care Ag	Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US7078479B2 (en) *	2001-11-09	2006-07-18	Novo Nordisk Healthcare A/G	Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119743A1 (en) *	2001-11-09	2003-06-26	Rasmus Rojkjaer	Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
AU2002351755A1 (en) *	2001-12-21	2003-07-15	Novo Nordisk A/S	Liquid composition of modified factor vii polypeptides
EP1458408B1 (de) *	2001-12-21	2009-04-15	Novo Nordisk Health Care AG	Flüssige zusammensetzung aus faktor vii polypeptiden
KR20040065278A (ko) *	2001-12-21	2004-07-21	노보 노르디스크 에이/에스	변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) *	2002-05-03	2004-01-15	Hanne Nedergaard	Stabilised solid compositions of modified factor VII
AU2003230367A1 (en) *	2002-05-10	2003-11-11	Neurocrine Biosciences, Inc.	Substituted piperazine as melanocortin receptors ligands
CN1671410B (zh) *	2002-06-21	2010-05-12	诺和诺德医疗保健公司	因子ⅶ多肽的稳定化固体组合物
FR2841854B1 (fr) *	2002-07-04	2004-09-24	Bosch Gmbh Robert	Dispositif d'assistance de freinage
AT501088A2 (de) *	2002-12-18	2006-06-15	Bio Prod & Bio Eng Ag	Stabile therapeutische proteine
AU2004222625A1 (en) *	2003-03-18	2004-09-30	Novo Nordisk Health Care Ag	Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) *	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
RU2364609C2 (ru) *	2003-05-23	2009-08-20	Ново Нордиск Хелт Кэр Аг	Стабилизация белка в растворе
EP1641487B1 (de) *	2003-06-25	2012-02-29	Novo Nordisk Health Care AG	Flüssige zusammensetzungen von factor vii polypeptiden
WO2005002615A1 (en) *	2003-07-01	2005-01-13	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) *	2003-08-14	2015-01-14	ノボノルディスクヘルスケアアクチェンゲゼルシャフト	第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) *	2003-12-19	2012-03-21	诺和诺德医疗保健公司	因子vii多肽的稳定化固体组合物
CN101184474B (zh) *	2005-04-28	2013-05-29	诺和诺德医疗保健公司	含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法

2004
- 2004-06-30 WO PCT/DK2004/000465 patent/WO2005002615A1/en not_active Ceased
- 2004-06-30 DE DE602004023848T patent/DE602004023848D1/de not_active Expired - Lifetime
- 2004-06-30 JP JP2006515737A patent/JP5306597B2/ja not_active Expired - Fee Related
- 2004-06-30 EP EP04738962A patent/EP1644030B1/de not_active Expired - Lifetime
- 2004-06-30 AT AT04738962T patent/ATE446768T1/de not_active IP Right Cessation
- 2004-06-30 ES ES04738962T patent/ES2335994T3/es not_active Expired - Lifetime
2005
- 2005-12-15 US US11/304,427 patent/US20060166882A1/en not_active Abandoned
2009
- 2009-08-06 US US12/536,872 patent/US20100166730A1/en not_active Abandoned
2012
- 2012-03-06 JP JP2012049441A patent/JP2012153696A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ES2335994T3 (es)	2010-04-07
DE602004023848D1 (de)	2009-12-10
EP1644030A1 (de)	2006-04-12
EP1644030B1 (de)	2009-10-28
JP2012153696A (ja)	2012-08-16
JP5306597B2 (ja)	2013-10-02
WO2005002615A1 (en)	2005-01-13
JP2007507419A (ja)	2007-03-29
US20100166730A1 (en)	2010-07-01
US20060166882A1 (en)	2006-07-27

Legal Events

Date	Code	Title	Description
2010-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
MXPA05009914A (es)	2006-01-09	Composiciones farmaceuticas acuosas, liquidas de polipeptidos del factor vii.
Goodnough et al.	2003	Bloodless medicine: clinical care without allogeneic blood transfusion.
Esmon	2003	The protein C pathway
AU678439B2 (en)	1997-05-29	Process for the obtention of a biological adhesive comprising fibrinogen, factor XIII and fibronectin
Hirokawa et al.	1991	Regulatory mechanisms for thrombomodulin expression in human umbilical vein endothelial cells in vitro
Patanwala et al.	2011	Prothrombin complex concentrate for critical bleeding
Koo et al.	1999	Case report. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid).
ATE552031T1 (de)	2012-04-15	Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
JP2004075682A5 (de)	2006-09-28
TR200101903T2 (tr)	2001-11-21	Yeni malonik asit türevleri, bunların preparasyon işlemleri.
ATE446768T1 (de)	2009-11-15	Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
BG108514A (en)	2005-04-30	METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
DE69427650D1 (de)	2001-08-09	Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE3617753A1 (de)	1986-12-04	Gewebe-plasminogenaktivator, diesen enthaltende pharmazeutische formulierungen sowie ihre herstellung und ihre verwendung in der human- und veterinaermedizin
AT500670A1 (de)	2006-02-15	Arzneimittel zur lokalen anwendung
Kuklo et al.	2003	Perioperative blood and blood product management for spinal deformity surgery
Biesma et al.	1993	The efficacy of subcutaneous recombinant human erythropoietin in the correction of phlebotomy‐induced anemia in autologous blood donors
JP2004511492A5 (de)	2005-03-17
ATE303816T1 (de)	2005-09-15	Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
D'Ambra et al.	1990	Aprotinin, erythropoietin, and blood substitutes
ATE433743T1 (de)	2009-07-15	Ternäre eutektische gemische von lokalanaesthetika
WO2005017139A1 (en)	2005-02-24	Thrombin from venom of agkistrodon acutus used as drugs for the treatment of haemorrhage
WO2017117995A1 (zh)	2017-07-13	一种含有壳聚糖的蛋白胶及其使用方法
DE69719095D1 (de)	2003-03-20	Gallensauersälze mit physiologisch aktiven metalle und ihre verwendung zur therapeutischen behandlung
Somers et al.	1993	White clot syndrome associated with renal failure.